12-month data from pivotal randomized studies underscore Cordis' commitment to shaping the future of cardiovascular care.

MIAMI LAKES, Fla., Oct. 21, 2025 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, will share late-breaking 12-month results from two SELUTION SLR™ Drug-Eluting Balloon (DEB) coronary trials at Transcatheter Cardiovascular Therapeutics® (TCT®), the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).

TCT Late-Breaking Clinical Trials Session

The SELUTION4ISR and SELUTION DeNovo results will be presented in the first Late-Breaking Clinical Trials session on Sunday, October 26, 2025, at 11:00 a.m. PST in San Francisco.

Professor Christian M. Spaulding, Hôpital Européen Georges-Pompidou, Paris, France, will

See Full Page